Retinoblastoma: Treatment and Survival in Great Britain 1963 to 2002

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2008 Oct 8

PMID 18838414

Citations 41

Authors

A MacCarthy

J M Birch

G J Draper

J L Hungerford

J E Kingston

M E Kroll

C A Stiller

T J Vincent

M F G Murphy

Affiliations

Soon will be listed here.

Abstract

Aim: This paper describes the treatment and survival of 1576 children with retinoblastoma in Great Britain diagnosed 1963-2002.

Methods: Survival rates were analysed according to period of diagnosis and tumour laterality.

Results: Survival was calculated by calendar period of diagnosis, 1963-1982 and 1983-2002. For both unilateral and bilateral retinoblastoma, survival improved between the two periods. The survival curves for the two periods were significantly different: for unilateral retinoblastoma p<0.00001, for bilateral p<0.01. For unilateral cases, the estimated 5-year survival rates rose from 85% for those diagnosed in 1963-1967 to 97% for those diagnosed in 1998-2002. The equivalent rates for bilateral cases were 88% and 100%.

Conclusion: Survival rates were already high at the start of the study period. They increased with changes in treatment regimens.

Citing Articles

Global health inequities in retinoblastoma: a 1990-2021 analysis across socio-demographic index regions.

Li X, Chang Y, Zhao X, Liu X, Zhang Y, Wang X Front Public Health. 2025; 13:1513526.

PMID: 40061466 PMC: 11885149. DOI: 10.3389/fpubh.2025.1513526.

Global, regional, and national burden of retinoblastoma in infants and young children: findings from the global burden of disease study 1990-2021.

Chen J, Cao X, Xu S, Chen X, Xie R, Ye G EClinicalMedicine. 2024; 76:102860.

PMID: 39398496 PMC: 11470412. DOI: 10.1016/j.eclinm.2024.102860.

Survival and Health Care Burden of Children With Retinoblastoma in Europe.

Virgili G, Capocaccia R, Botta L, Bennett D, Hadjistilianou T, Innos K JAMA Ophthalmol. 2024; .

PMID: 39388193 PMC: 11581545. DOI: 10.1001/jamaophthalmol.2024.4140.

Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.

Zeng C, Du N, He L, Wang H, Zhao T, Jia R Sci Rep. 2024; 14(1):17389.

PMID: 39075052 PMC: 11286795. DOI: 10.1038/s41598-024-67155-x.

Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom.

Millen G, Lawford A, Duncan C, Jenkinson H, Veal G, Barnett S Br J Cancer. 2024; 131(3):491-497.

PMID: 38871807 PMC: 11300439. DOI: 10.1038/s41416-024-02728-1.